{"title":"[从慢性炎症性脱髓鞘性多根神经病变中分离出来的疾病:抗髓鞘相关糖蛋白神经病和自身免疫性神经病变]。","authors":"Masanori Nakajima, Ken-Ichi Kaida","doi":"10.11477/mf.188160960770010035","DOIUrl":null,"url":null,"abstract":"<p><p>Anti-myelin-associated glycoprotein (Anti-MAG) neuropathy and autoimmune nodopathies with antibodies targeting nodal or paranodal proteins have recently been reclassified as distinct conditions, separate from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This distinction is based on the clinical homogeneity observed in antibody-positive cases, their unique response to treatment compared to CIDP, and evidence indicating the pathogenic role of these autoantibodies. The significance of identifying conditions outside the CIDP category lies in the elucidation of their distinct pathological mechanisms and providing appropriate immunotherapy accordingly. We hope that the various pathologies currently grouped under CIDP will be further clarified in the future, leading to the elimination of CIDP variants with different pathophysiologies.</p>","PeriodicalId":52507,"journal":{"name":"Brain and Nerve","volume":"77 1","pages":"35-42"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Diseases Separated from Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Anti-Myelin-Associated Glycoprotein Neuropathy and Autoimmune Nodopathy].\",\"authors\":\"Masanori Nakajima, Ken-Ichi Kaida\",\"doi\":\"10.11477/mf.188160960770010035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Anti-myelin-associated glycoprotein (Anti-MAG) neuropathy and autoimmune nodopathies with antibodies targeting nodal or paranodal proteins have recently been reclassified as distinct conditions, separate from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This distinction is based on the clinical homogeneity observed in antibody-positive cases, their unique response to treatment compared to CIDP, and evidence indicating the pathogenic role of these autoantibodies. The significance of identifying conditions outside the CIDP category lies in the elucidation of their distinct pathological mechanisms and providing appropriate immunotherapy accordingly. We hope that the various pathologies currently grouped under CIDP will be further clarified in the future, leading to the elimination of CIDP variants with different pathophysiologies.</p>\",\"PeriodicalId\":52507,\"journal\":{\"name\":\"Brain and Nerve\",\"volume\":\"77 1\",\"pages\":\"35-42\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Brain and Nerve\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11477/mf.188160960770010035\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain and Nerve","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11477/mf.188160960770010035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
[Diseases Separated from Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Anti-Myelin-Associated Glycoprotein Neuropathy and Autoimmune Nodopathy].
Anti-myelin-associated glycoprotein (Anti-MAG) neuropathy and autoimmune nodopathies with antibodies targeting nodal or paranodal proteins have recently been reclassified as distinct conditions, separate from chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This distinction is based on the clinical homogeneity observed in antibody-positive cases, their unique response to treatment compared to CIDP, and evidence indicating the pathogenic role of these autoantibodies. The significance of identifying conditions outside the CIDP category lies in the elucidation of their distinct pathological mechanisms and providing appropriate immunotherapy accordingly. We hope that the various pathologies currently grouped under CIDP will be further clarified in the future, leading to the elimination of CIDP variants with different pathophysiologies.